| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with Qi Diagnostics Limited ("Qi Diagnostics") to distribute the KetoAir™, a breathalyzer device and related accessories, including current and future models, in key regions including North America, South America, the United Kingdom, and the European Union.
KetoAir™ is a pioneering breathalyzer device equipped with AI-enabled software, designed for ketogenic health management (United States FDA registration number: 3026284320). Through the integration of nanosensor-based technology and advanced AI algorithms, the KetoAir™ breathalyzer not only measures the keto status but also logs diet records directly into the KetoAir app, available in the Apple App store and Google Play store.
Moreover, the AI nutritionist within the app offers personalized nutritional and exercise recommendations tailored to each user's health goals. It marks the first of its kind in the market, offering users a comprehensive solution to monitor and optimize their ketosis state and body fat burning rate. The device provides accurate and instant results with a single blow, enabling users to track how different foods and activities impact their ketone level.
"We are excited to extend our exclusive distribution agreement for KetoAir™ with Qi Diagnostics," stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. "KetoAir™ is the first breathalyzer on the market that uses an AI nutritionist bundled with a nanosensor-based breathalyzer for ketogenic health management. Our primary focus will be on targeting the diabetes reversal and obesity management markets. Given the effectiveness of the ketogenic diet as a treatment option for both diabetes and weight management, we believe there is tremendous potential in addressing these critical health concerns. With the soft launch planned for 2024 and a full-scale launch in 2025, we are excited to bring KetoAir™ to individuals seeking to enhance their health and wellness journey."
Posted In: ALBT
